Read + Share
Kumar A. Can sorafenib use influence outcome when comparing stereotactic body radiation
therapy with radiofrequency ablation in patients with hepatocellular carcinoma? J Hepatol 2020 May 11. pii: S0168-8278(20)30175.
PMID: 32409208
|
 |
|
Kumar A. Can sorafenib use influence outcome when comparing stereotactic body radiation
therapy with radiofrequency ablation in patients with hepatocellular carcinoma? J Hepatol 2020 May 11. pii: S0168-8278(20)30175.
PMID: 32409208
|
|
|
|